BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35412712)

  • 21. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
    Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA
    Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MR Imaging Features of Anaplastic Pleomorphic Xanthoastrocytoma Mimicking High-Grade Astrocytoma.
    She D; Liu J; Xing Z; Zhang Y; Cao D; Zhang Z
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1446-1452. PubMed ID: 29903923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.
    Chamberlain MC
    J Neurooncol; 2013 Sep; 114(2):237-40. PubMed ID: 23756728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ganglioglioma Progression to Combined Anaplastic Ganglioglioma and Anaplastic Pleomorphic Xanthoastrocytoma. Case Report and Literature Review.
    Rosselló A; Plans G; Vidal-Sarró N; Fernández-Coello A; Gabarrós A
    World Neurosurg; 2017 Dec; 108():996.e17-996.e25. PubMed ID: 28939541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.
    Piña Y; Fusco MJ; Macaulay RJ; Walko CM; Peguero E; Evernden BR; Smalley KS; Forsyth P
    J Neurol; 2020 Mar; 267(3):783-790. PubMed ID: 31748891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.
    Tonse R; Gupta T; Epari S; Shastri JG; Gurav M; Bano N; Jalali R
    J Neurooncol; 2018 Jan; 136(2):343-350. PubMed ID: 29147864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Epithelioid glioblastoma with BRAF V600E mutation: a clinicopathological and molecular study].
    Zheng LM; Gong J; Zou Y; Zhang MN; Yu TP; Hou J; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):229-235. PubMed ID: 33677887
    [No Abstract]   [Full Text] [Related]  

  • 28. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.
    Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH
    Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron emission tomography in three children with pleomorphic xanthoastrocytoma.
    Etzl MM; Kaplan AM; Moss SD; Spataro J; Bonstelle CT; Lawson MA; Bandy DJ
    J Child Neurol; 2002 Jul; 17(7):522-7. PubMed ID: 12269732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rare clinical presentations of pleomorphic xanthoastrocytoma with a high proliferative index: Two case reports.
    Nagaishi M; Nakae R; Fujii Y; Inoue Y; Sugiura Y; Takano I; Tanaka Y; Suzuki K
    Medicine (Baltimore); 2020 Jan; 99(3):e18880. PubMed ID: 32011515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.
    Andrews LJ; Thornton ZA; Saincher SS; Yao IY; Dawson S; McGuinness LA; Jones HE; Jefferies S; Short SC; Cheng HY; McAleenan A; Higgins JPT; Kurian KM
    Neuro Oncol; 2022 Apr; 24(4):528-540. PubMed ID: 34718782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New IDH1 I113T mutation associated with BRAF V600E mutation: new driver of gliomagenesis?
    Tabouret E; Fina F; Vincentelli F; Nanni I; Figarella-Branger D
    J Neurol Sci; 2014 Jul; 342(1-2):204-6. PubMed ID: 24857351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.
    Usubalieva A; Pierson CR; Kavran CA; Huntoon K; Kryvenko ON; Mayer TG; Zhao W; Rock J; Ammirati M; Puduvalli VK; Lehman NL
    J Neuropathol Exp Neurol; 2015 Oct; 74(10):960-9. PubMed ID: 26352988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group.
    Ono T; Sasajima T; Shimizu H; Natsumeda M; Kanamori M; Asano K; Beppu T; Matsuda K; Ichikawa M; Fujii Y; Ohkuma H; Ogasawara K; Sonoda Y; Saito K; Nobusawa S; Nakazato Y; Kitanaka C; Kayama T; Tominaga T;
    Neurol Med Chir (Tokyo); 2020 Nov; 60(11):543-552. PubMed ID: 33071274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MR Imaging Characteristics and ADC Histogram Metrics for Differentiating Molecular Subgroups of Pediatric Low-Grade Gliomas.
    Shrot S; Kerpel A; Belenky J; Lurye M; Hoffmann C; Yalon M
    AJNR Am J Neuroradiol; 2022 Sep; 43(9):1356-1362. PubMed ID: 36007944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined Diffuse Astrocytoma and Pleomorphic Xanthoastrocytoma Grade III Sharing IDH1 R132H Mutation.
    Tourne M; Tauziède-Espariat A; Dezamis E; Saffroy R; Dhermain F; Chrétien F; Varlet P
    World Neurosurg; 2018 Aug; 116():316-321. PubMed ID: 29859360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pleomorphic xanthoastrocytoma in the brainstem with BRAF V600E mutation: A case report.
    Guo Y; Ning G; Feng M; Qu HB
    Asian J Surg; 2023 Aug; 46(8):3371-3373. PubMed ID: 36977615
    [No Abstract]   [Full Text] [Related]  

  • 38. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
    Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
    PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment.
    Atahan C; Arslantas E; Ersen Danyeli A; Celik L; Bozkurt G; Ugurluer G; Corapcioglu FV; Ozyar E
    J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1005-e1009. PubMed ID: 37700448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebellar Pleomorphic Xanthoastrocytoma with BRAF V600E Mutation.
    Kim SH; Hwang K; Lee KS; Choe G; Kim CY
    World Neurosurg; 2020 Jul; 139():577-581. PubMed ID: 32348888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.